Margaret Fischl

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

HIV-1

Procedures

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Jacobson Jeffrey M; Saag Michael S; Thompson Melanie A; Fischl Margaret A; Liporace Ralph; Reichman Richard C; Redfield Robert R; Fichtenbaum Carl J; Zingman Barry S; Patel Mahesh C; Murga Jose D; Pemrick Suzanne M; D'Ambrosio Paul; Michael Marti; Kroger Hans; Ly Hieu; Rotshteyn Yakov; Buice Robert; Morris Stephen A; Stavola Joseph J; Maddon Paul J; Kremer Alton B; Olson William C
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
Hammer Scott M; Eron Joseph J; Reiss Peter; Schooley Robert T; Thompson Melanie A; Walmsley Sharon; Cahn Pedro; Fischl Margaret A; Gatell Jose M; Hirsch Martin S; Jacobsen Donna M; Montaner Julio S G; Richman Douglas D; Yeni Patrick G; Volberding Paul A;
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
Demeter Lisa M; DeGruttola Victor; Lustgarten Stephanie; Bettendorf Daniel; Fischl Margaret; Eshleman Susan; Spreen William; Nguyen Bach-Yen; Koval Christine E; Eron Joseph J; Hammer Scott; Squires Kathleen
Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Margaret Fischl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Jacobson Jeffrey M; Saag Michael S; Thompson Melanie A; Fischl Margaret A; Liporace Ralph; Reichman Richard C; Redfield Robert R; Fichtenbaum Carl J; Zingman Barry S; Patel Mahesh C; Murga Jose D; Pemrick Suzanne M; D'Ambrosio Paul; Michael Marti; Kroger Hans; Ly Hieu; Rotshteyn Yakov; Buice Robert; Morris Stephen A; Stavola Joseph J; Maddon Paul J; Kremer Alton B; Olson William C
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
The Journal of infectious diseases 2008;198(9):1345-52.
2008: Hammer Scott M; Eron Joseph J; Reiss Peter; Schooley Robert T; Thompson Melanie A; Walmsley Sharon; Cahn Pedro; Fischl Margaret A; Gatell Jose M; Hirsch Martin S; Jacobsen Donna M; Montaner Julio S G; Richman Douglas D; Yeni Patrick G; Volberding Paul A;
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2008;300(5):555-70.
2008: Demeter Lisa M; DeGruttola Victor; Lustgarten Stephanie; Bettendorf Daniel; Fischl Margaret; Eshleman Susan; Spreen William; Nguyen Bach-Yen; Koval Christine E; Eron Joseph J; Hammer Scott; Squires Kathleen
Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
HIV clinical trials 2008;9(1):11-25.
2008: Smith Kimberly Y; Weinberg Winkler G; Dejesus Edwin; Fischl Margaret A; Liao Qiming; Ross Lisa L; Pakes Gary E; Pappa Keith A; Lancaster C Tracey;
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
AIDS research and therapy 2008;5():5.
2007: Higgins Niamh; Zingman Barry S; Slish Judianne; Reichman Richard C; Fischl Margaret A; Gripshover Barbara; Tooley Kelly; Boston Naomi; Forrest Alan; Brazeau Dan; Catanzaro Linda M; DiFrancesco Robin; Lliguicota Francesco; Ma Qing; Morse Gene D
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.
The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2007;16(6):488-94.
2007: Slish Judianne; Ma Qing; Zingman Barry S; Reichman Richard C; Fischl Margaret A; Gripshover Barbara; Forrest Alan; Brazeau Dan; Boston Naomi S; Catanzaro Linda; DiFrancesco Robin; Morse Gene D
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Therapeutic drug monitoring 2007;29(5):560-5.
2007: King William D; Defreitas Donna; Smith Kimberly; Andersen Janet; Perry Lisa Patton; Adeyemi Toyin; Mitty Jennifer; Fritsche Jan; Jeffries Carrie; Littles Melvin; Fischl Margaret; Pavlov Gregory; Mildvan Donna;
Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive study.
AIDS patient care and STDs 2007;21(8):551-63.
2007: Tebas Pablo; Zhang Jiameng; Yarasheski Kevin; Evans Scott; Fischl Margaret A; Shevitz Abby; Feinberg Judith; Collier Ann C; Shikuma Cecilia; Brizz Barbara; Sattler Fred;
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
Journal of acquired immune deficiency syndromes (1999) 2007;45(2):193-200.
2007: DiFrancesco Robin; Fischl Margaret A; Donnelly Julie; Zingman Barry S; McCance-Katz Elinore F; Moody David E; Reichman Richard C; Gripshover Barbara; Morse Gene D
Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
Journal of pharmaceutical and biomedical analysis 2007;44(1):188-95.
2007: Ma Qing; Brazeau Daniel; Zingman Barry S; Reichman Richard C; Fischl Margaret A; Gripshover Barbara M; Venuto Charles S; Slish Judianne C; DiFrancesco Robin; Forrest Alan; Morse Gene D
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
Pharmacogenomics 2007;8(3):227-35.
2007: Keil Kim; Hochreitter Jill; DiFrancesco Robin; Zingman Barry S; Reichman Richard C; Fischl Margaret A; Gripshover Barbara; Morse Gene D
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
Therapeutic drug monitoring 2007;29(1):103-9.
2007: Fischl Margaret A; Collier Ann C; Mukherjee A Lisa; Feinberg Judith E; Demeter Lisa M; Tebas Pablo; Giuliano Marina; Dehlinger Marjorie; Garren Kevin; Brizz Barbara; Bassett Roland
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
AIDS (London, England) 2007;21(3):325-33.
2007: Moore Jeff D; Acosta Edward P; Johnson Victoria A; Bassett Roland; Eron Joseph J; Fischl Margaret A; Long Mary C; Kuritzkes Daniel R; Sommadossi Jean-Pierre
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Antiviral therapy 2007;12(6):981-6.
2006: Kilby J Michael; Bucy R Pat; Mildvan Donna; Fischl Margaret; Santana-Bagur Jorge; Lennox Jeff; Pilcher Chris; Zolopa Andrew; Lawrence Jody; Pollard Richard B; Habib Raphaelle El; Sahner David; Fox Lawrence; Aga Evgenia; Bosch Ronald J; Mitsuyasu Ronald;
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
The Journal of infectious diseases 2006;194(12):1672-6.
2006: Hammer Scott M; Saag Michael S; Schechter Mauro; Montaner Julio S G; Schooley Robert T; Jacobsen Donna M; Thompson Melanie A; Carpenter Charles C J; Fischl Margaret A; Gazzard Brian G; Gatell Jose M; Hirsch Martin S; Katzenstein David A; Richman Douglas D; Vella Stefano; Yeni Patrick G; Volberding Paul A;
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):827-43.
2006: Hammer Scott M; Saag Michael S; Schechter Mauro; Montaner Julio S G; Schooley Robert T; Jacobsen Donna M; Thompson Melanie A; Carpenter Charles C J; Fischl Margaret A; Gazzard Brian G; Gatell Jose M; Hirsch Martin S; Katzenstein David A; Richman Douglas D; Vella Stefano; Yeni Patrick G; Volberding Paul A;
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2006;296(7):827-43.
2006: Krown Susan E; Lee Jeannette Y; Lin Lan; Fischl Margaret A; Ambinder Richard; Von Roenn Jamie H
Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.
Journal of acquired immune deficiency syndromes (1999) 2006;41(2):149-53.
2005: Collier Ann C; Ribaudo Heather; Mukherjee A Lisa; Feinberg Judith; Fischl Margaret A; Chesney Margaret;
A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.
The Journal of infectious diseases 2005;192(8):1398-406.
2005: Smith Patrick F; Robbins Gregory K; Shafer Robert W; Wu Hulin; Yu Song; Hirsch Martin S; Merigan Thomas C; Park Jeong-Gun; Forrest Alan; Fischl Margaret A; Morse Gene D;
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Antimicrobial agents and chemotherapy 2005;49(8):3558-61.
2005: Smith Patrick F; Dicenzo Robert; Forrest Alan; Shelton Mark; Friedland Gerald; Para Michael; Pollard Richard; Fischl Margaret; DiFrancesco Robin; Morse Gene D
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
Clinical pharmacokinetics 2005;44(1):99-109.
2004: Demeter Lisa M; Ribaudo Heather J; Erice Alejo; Eshleman Susan H; Hammer Scott M; Hellmann Nicholas S; Fischl Margaret A;
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(4):552-8.
2004: Yeni Patrick G; Hammer Scott M; Hirsch Martin S; Saag Michael S; Schechter Mauro; Carpenter Charles C J; Fischl Margaret A; Gatell Jose M; Gazzard Brian G; Jacobsen Donna M; Katzenstein David A; Montaner Julio S G; Richman Douglas D; Schooley Robert T; Thompson Melanie A; Vella Stefano; Volberding Paul A
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2004;292(2):251-65.
2004: DiCenzo Robert; Forrest Alan; Fischl Margaret A; Collier Ann; Feinberg Judith; Ribaudo Heather; DiFrancecso Robin; Morse Gene D;
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
Antimicrobial agents and chemotherapy 2004;48(3):918-23.
2004: Malhotra Uma; Bosch Ronald J; Chan Ellen; Wang Rui; Fischl Margaret A; Collier Ann C; McElrath M Juliana
Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.
The Journal of infectious diseases 2004;189(3):515-9.
2003: Hammer Scott M; Bassett Roland; Squires Kathleen E; Fischl Margaret A; Demeter Lisa M; Currier Judith S; Mellors John W; Morse Gene D; Eron Joseph J; Santana Jorge L; DeGruttola Victor;
A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.
Antiviral therapy 2003;8(6):507-18.
2003: Robbins Gregory K; De Gruttola Victor; Shafer Robert W; Smeaton Laura M; Snyder Sally W; Pettinelli Carla; Dubé Michael P; Fischl Margaret A; Pollard Richard B; Delapenha Robert; Gedeon Linda; van der Horst Charles; Murphy Robert L; Becker Mark I; D'Aquila Richard T; Vella Stefano; Merigan Thomas C; Hirsch Martin S;
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
The New England journal of medicine 2003;349(24):2293-303.
2003: Fischl Margaret A; Burnside Alfred E; Farthing Charles E; Thompson Melanie A; Bellos Nicholaos C; Williams Vanessa C; Kauf Teresa L; Wannamaker Paul G; Shaefer Mark S;
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Pharmacotherapy 2003;23(11):1432-40.
2003: Hirsch Martin S; Steigbigel Roy T; Staszewski Scholomo; McMahon Deborah; Fischl Margaret A; Hirschel Bernard; Squires Kathleen; DiNubile Mark J; Harvey Charlotte M; Chen Joshua; Leavitt Randi Y;
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(8):1119-24.
2003: Fischl Margaret A; Ribaudo Heather J; Collier Ann C; Erice Alejo; Giuliano Marina; Dehlinger Marjorie; Eron Joseph J; Saag Michael S; Hammer Scott M; Vella Stefano; Morse Gene D; Feinberg Judith E; Demeter Lisa M; Eshleman Susan H;
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
The Journal of infectious diseases 2003;188(5):625-34.
2003: DiCenzo Robert; Forrest Alan; Squires Kathleen E; Hammer Scott M; Fischl Margaret A; Wu Hulin; Cha Raymond; Morse Gene D;
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
Antimicrobial agents and chemotherapy 2003;47(6):1929-35.
2003: Daikos G L; Cleary T; Rodriguez A; Fischl M A
Multidrug-resistant tuberculous meningitis in patients with AIDS.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2003;7(4):394-8.
2003: Morse Gene D; Fischl Margaret A; Shelton Mark J; Cox Steve R; Thompson Leslie; Della-Coletta Andrew A; Freimuth William W
Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection.
Clinical drug investigation 2003;23(4):255-61.
2002: Young Benjamin; Fischl Margaret A; Wilson Helene M; Finn Tyler S; Jensen Erin H; DiNubile Mark J; Zeldin Robert K
Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
Journal of acquired immune deficiency syndromes (1999) 2002;31(5):478-82.
2002: Gulick Roy M; Hu X Joan; Fiscus Susan A; Fletcher Courtney V; Haubrich Richard; Cheng Hailong; Acosta Edward; Lagakos Stephen W; Swanstrom Ronald; Freimuth William; Snyder Sally; Mills Charlotte; Fischl Margaret; Pettinelli Carla; Katzenstein David
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
The Journal of infectious diseases 2002;186(5):626-33.
2002: Yeni Patrick G; Hammer Scott M; Carpenter Charles C J; Cooper David A; Fischl Margaret A; Gatell Jose M; Gazzard Brian G; Hirsch Martin S; Jacobsen Donna M; Katzenstein David A; Montaner Julio S G; Richman Douglas D; Saag Michael S; Schechter Mauro; Schooley Robert T; Thompson Melanie A; Vella Stefano; Volberding Paul A
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2002;288(2):222-35.
2002: Demeter Lisa M; Bosch Ronald J; Coombs Robert W; Fiscus Susan; Bremer James; Johnson Victoria A; Erice Alejo; Jackson J Brooks; Spector Stephen A; Squires Kathleen M; Fischl Margaret A; Hughes Michael D; Hammer Scott M
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.
Journal of clinical microbiology 2002;40(6):2089-94.
2002: Ait-Khaled Mounir; Rakik Abdelrahim; Griffin Philip; Cutrell Amy; Fischl Margaret A; Clumeck Nathan; Greenberg Stephen B; Rubio Rafael; Peters Barry S; Pulido Federico; Gould Jayne; Pearce Gill; Spreen William; Tisdale Margaret; Lafon Steve;
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Antiviral therapy 2002;7(1):43-51.
2002: Kirkland Larry R; Fischl Margaret A; Tashima Karen T; Paar David; Gensler Thomas; Graham Neil M; Gao Haitao; Rosenzweig Jacqueline R Carranza; McClernon Daniel R; Pittman Ginger; Hessenthaler Siegrid M; Hernandez Jaime E;
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(4):511-8.
2001: Demeter L M; Hughes M D; Coombs R W; Jackson J B; Grimes J M; Bosch R J; Fiscus S A; Spector S A; Squires K E; Fischl M A; Hammer S M
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Annals of internal medicine 2001;135(11):954-64.
2001: Arduino J M; Fischl M A; Stanley K; Collier A C; Spiegelman D
Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?
AIDS research and human retroviruses 2001;17(12):1099-105.
2001: Huang W; De Gruttola V; Fischl M; Hammer S; Richman D; Havlir D; Gulick R; Squires K; Mellors J
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
The Journal of infectious diseases 2001;183(10):1455-65.
2000: Fischl M
Clinical trials within the Florida Department of Corrections.
Medicine and health, Rhode Island 2000;83(12):393.
2000: Fletcher C V; Acosta E P; Cheng H; Haubrich R; Fischl M; Raasch R; Mills C; Hu X J; Katzenstein D; Remmel R P; Gulick R M;
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
AIDS (London, England) 2000;14(16):2495-501.
2000: Gulick R M; Hu X J; Fiscus S A; Fletcher C V; Haubrich R; Cheng H; Acosta E; Lagakos S W; Swanstrom R; Freimuth W; Snyder S; Mills C; Fischl M; Pettinelli C; Katzenstein D
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
The Journal of infectious diseases 2000;182(5):1375-84.
2000: Goodgame J C; Pottage J C; Jablonowski H; Hardy W D; Stein A; Fischl M; Morrow P; Feinberg J; Brothers C H; Vafidis I; Nacci P; Yeo J; Pedneault L
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Antiviral therapy 2000;5(3):215-25.
2000: Demeter L M; Shafer R W; Meehan P M; Holden-Wiltse J; Fischl M A; Freimuth W W; Para M F; Reichman R C
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
Antimicrobial agents and chemotherapy 2000;44(3):794-7.
2000: Morse G D; Reichman R C; Fischl M A; Para M; Leedom J; Powderly W; Demeter L M; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
Antiviral research 2000;45(1):47-58.
2000: Carpenter C C; Cooper D A; Fischl M A; Gatell J M; Gazzard B G; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schechter M; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(3):381-90.
1999: Fischl M A
Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
AIDS (London, England) 1999;13 Suppl 1():S49-59.
1999: Friedland G H; Pollard R; Griffith B; Hughes M; Morse G; Bassett R; Freimuth W; Demeter L; Connick E; Nevin T; Hirsch M; Fischl M
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
Journal of acquired immune deficiency syndromes (1999) 1999;21(4):281-92.
1999: Para M F; Meehan P; Holden-Wiltse J; Fischl M; Morse G; Shafer R; Demeter L M; Wood K; Nevin T; Virani-Ketter N; Freimuth W W
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.
Antimicrobial agents and chemotherapy 1999;43(6):1373-8.
1999: Kuritzkes D R; Marschner I; Johnson V A; Bassett R; Eron J J; Fischl M A; Murphy R L; Fife K; Maenza J; Rosandich M E; Bell D; Wood K; Sommadossi J P; Pettinelli C
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
AIDS (London, England) 1999;13(6):685-94.
1999: Zhou X J; Sheiner L B; D'Aquila R T; Hughes M D; Hirsch M S; Fischl M A; Johnson V A; Myers M; Sommadossi J P
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Antimicrobial agents and chemotherapy 1999;43(1):121-8.
1998: Henry K; Erice A; Tierney C; Balfour H H; Fischl M A; Kmack A; Liou S H; Kenton A; Hirsch M S; Phair J; Martinez A; Kahn J O
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(4):339-49.
1998: Hughes M D; Daniels M J; Fischl M A; Kim S; Schooley R T
CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.
AIDS (London, England) 1998;12(14):1823-32.
1998: Demeter L M; Meehan P M; Morse G; Fischl M A; Para M; Powderly W; Leedom J; Holden-Wiltse J; Greisberger C; Wood K; Timpone J; Wathen L K; Nevin T; Resnick L; Batts D H; Reichman R C
Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(2):135-44.
1998: Daikos G L; Uttamchandani R B; Tuda C; Fischl M A; Miller N; Cleary T; Saldana M J
Disseminated miliary tuberculosis of the skin in patients with AIDS: report of four cases.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(1):205-8.
1998: Northfelt D W; Dezube B J; Thommes J A; Miller B J; Fischl M A; Friedman-Kien A; Kaplan L D; Du Mond C; Mamelok R D; Henry D H
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2445-51.
1998: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 1998;280(1):78-86.
1998: Zackin R; Marschner I; Andersen J; Cowles M K; De Gruttola V; Hammer S; Fischl M; Cotton D
Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping.
The Journal of infectious diseases 1998;177(3):761-5.
1998: Marschner I C; Collier A C; Coombs R W; D'Aquila R T; DeGruttola V; Fischl M A; Hammer S M; Hughes M D; Johnson V A; Katzenstein D A; Richman D D; Smeaton L M; Spector S A; Saag M S
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
The Journal of infectious diseases 1998;177(1):40-7.
1997: Fischl M A; Richman D D; Saag M; Meng T C; Squires K E; Holden-Wiltse J; Meehan P M
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16(4):247-53.
1997: Hammer S M; Squires K E; Hughes M D; Grimes J M; Demeter L M; Currier J S; Eron J J; Feinberg J E; Balfour H H; Deyton L R; Chodakewitz J A; Fischl M A
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
The New England journal of medicine 1997;337(11):725-33.
1997: Qayyum Q J; Scerpella E G; Moreno J N; Fischl M A
Report of 24 cases of Listeria monocytogenes infection at the University of Miami Medical Center.
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición 1997;49(4):265-70.
1997: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 1997;277(24):1962-9.
1997: Hughes M D; Johnson V A; Hirsch M S; Bremer J W; Elbeik T; Erice A; Kuritzkes D R; Scott W A; Spector S A; Basgoz N; Fischl M A; D'Aquila R T
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Annals of internal medicine 1997;126(12):929-38.
1997: Fischl M A; Richman D D; Flexner C; Para M F; Haubrich R; Karim A; Yeramian P; Holden-Wiltse J; Meehan P M
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;15(1):28-34.
1997: Simpson D M; Slasor P; Dafni U; Berger J; Fischl M A; Hall C
Analysis of myopathy in a placebo-controlled zidovudine trial.
Muscle & nerve 1997;20(3):382-5.
1997: Morse G D; Fischl M A; Shelton M J; Cox S R; Driver M; DeRemer M; Freimuth W W
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
Antimicrobial agents and chemotherapy 1997;41(1):169-74.
1996: Welles S L; Jackson J B; Yen-Lieberman B; Demeter L; Japour A J; Smeaton L M; Johnson V A; Kuritzkes D R; D'Aquila R T; Reichelderfer P A; Richman D D; Reichman R; Fischl M; Dolin R; Coombs R W; Kahn J O; McLaren C; Todd J; Kwok S; Crumpacker C S
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
The Journal of infectious diseases 1996;174(4):696-703.
1996: Lorenzo E; Herrera R J; Lai S; Fischl M A; Hill M D
The Tat and C2-V3 envelope genes in the molecular epidemiology of human immunodeficiency virus-1.
Virology 1996;221(2):310-7.
1996: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Sáag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
JAMA : the journal of the American Medical Association 1996;276(2):146-54.
1996: D'Aquila R T; Hughes M D; Johnson V A; Fischl M A; Sommadossi J P; Liou S H; Timpone J; Myers M; Basgoz N; Niu M; Hirsch M S
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Annals of internal medicine 1996;124(12):1019-30.
1996: Mildvan D; Bassiakos Y; Zucker M L; Hyslop N; Krown S E; Sacks H S; Zachary J; Paredes J; Fessel W J; Rhame F; Kramer F; Fischl M A; Poiesz B; Wood K; Ruprecht R M; Kim J; Grossberg S E; Kasdan P; Bergé P; Marshak A; Pettinelli C
Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
Antiviral therapy 1996;1(2):77-88.
1996: Fischl M A; Finkelstein D M; He W; Powderly W G; Triozzi P L; Steigbigel R T
A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(4):379-84.
1996: Morse G D; Fischl M A; Shelton M J; Borin M T; Driver M R; DeRemer M; Lee K; Wajszczuk C P
Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
Antimicrobial agents and chemotherapy 1996;40(3):767-71.
1996: Jacobson M A; Gundacker H; Hughes M; Fischl M; Volberding P
Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(1):45-52.
1995: Tierney M; Pottage J; Kessler H; Fischl M; Richman D; Merigan T; Powderly W; Smith S; Karim A; Sherman J
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(5):549-53.
1995: Volberding P A; Lagakos S W; Grimes J M; Stein D S; Rooney J; Meng T C; Fischl M A; Collier A C; Phair J P; Hirsch M S
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
The New England journal of medicine 1995;333(7):401-7.
1995: Dolin R; Amato D A; Fischl M A; Pettinelli C; Beltangady M; Liou S H; Brown M J; Cross A P; Hirsch M S; Hardy W D
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
Archives of internal medicine 1995;155(9):961-74.
1995: Meng T C; Fischl M A; Cheeseman S H; Spector S A; Resnick L; Boota A; Petrakis T; Wright B; Richman D D
Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;8(2):152-60.
1995: Moreno J N; Poblete R B; Maggio C; Gagnon S; Fischl M A
Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 1995;74(2):140-6.
1995: Reichman R C; Morse G D; Demeter L M; Resnick L; Bassiakos Y; Fischl M; Para M; Powderly W; Leedom J; Greisberger C
Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
The Journal of infectious diseases 1995;171(2):297-304.
1995: Fischl M A; Stanley K; Collier A C; Arduino J M; Stein D S; Feinberg J E; Allan J D; Goldsmith J C; Powderly W G
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
Annals of internal medicine 1995;122(1):24-32.
1994: Fogelman I; Lim L; Bassett R; Volberding P; Fischl M A; Stanley K; Cotton D J
Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG).
Journal of acquired immune deficiency syndromes 1994;7(10):1057-63.
1994: DeGruttola V; Beckett L A; Coombs R W; Arduino J M; Balfour H H; Rasheed S; Hollinger F B; Fischl M A; Volberding P
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
The Journal of infectious diseases 1994;169(4):713-21.
1994: Daikos G L; Lai S; Fischl M A
Hepatitis C virus infection in a sexually active inner city population. The potential for heterosexual transmission.
Infection 1994;22(2):72-6.
1994: Uttamchandani R B; Daikos G L; Reyes R R; Fischl M A; Dickinson G M; Yamaguchi E; Kramer M R
Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994;18(3):348-53.
1994: Fischl M A; Resnick L; Coombs R; Kremer A B; Pottage J C; Fass R J; Fife K H; Powderly W G; Collier A C; Aspinall R L
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
Journal of acquired immune deficiency syndromes 1994;7(2):139-47.
1994: Richman D D; Meng T C; Spector S A; Fischl M A; Resnick L; Lai S
Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
Journal of acquired immune deficiency syndromes 1994;7(2):135-8.
1994: Fischl M A
Combination antiretroviral therapy for HIV infection.
Hospital practice (Office ed.) 1994;29(1):43-8.
1993: Liang G S; Daikos G L; Serfling U; Zhu W Y; Pecoraro M; Leonardi C L; Fischl M A; Penneys N S
An evaluation of oral ulcers in patients with AIDS and AIDS-related complex.
Journal of the American Academy of Dermatology 1993;29(4):563-8.
1993: Collier A C; Coombs R W; Fischl M A; Skolnik P R; Northfelt D; Boutin P; Hooper C J; Kaplan L D; Volberding P A; Davis L G; Henrard D R; Weller S; Corey L
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
Annals of internal medicine 1993;119(8):786-93.
1993: Ellner J J; Hinman A R; Dooley S W; Fischl M A; Sepkowitz K A; Goldberger M J; Shinnick T M; Iseman M D; Jacobs W R
Tuberculosis symposium: emerging problems and promise.
The Journal of infectious diseases 1993;168(3):537-51.
1993: Lin D Y; Fischl M A; Schoenfeld D A
Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials.
Statistics in medicine 1993;12(9):835-42.
1993: Fischl M A; Olson R M; Follansbee S E; Lalezari J P; Henry D H; Frame P T; Remick S C; Salgo M P; Lin A H; Nauss-Karol C; Lieberman J; Soo W
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Annals of internal medicine 1993;118(10):762-9.
1993: Sidtis J J; Gatsonis C; Price R W; Singer E J; Collier A C; Richman D D; Hirsch M S; Schaerf F W; Fischl M A; Kieburtz K
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group.
Annals of neurology 1993;33(4):343-9.
1993: De Gruttola V; Wulfsohn M; Fischl M A; Tsiatis A
Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex.
Journal of acquired immune deficiency syndromes 1993;6(4):359-65.
1993: Fischl M A; Krown S E; O'Boyle K P; Mitsuyasu R; Miles S; Wernz J C; Volberding P A; Kahn J; Groopman J E; Feinberg J
Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group.
Journal of acquired immune deficiency syndromes 1993;6(3):259-64.
1993: Skowron G; Bozzette S A; Lim L; Pettinelli C B; Schaumburg H H; Arezzo J; Fischl M A; Powderly W G; Gocke D J; Richman D D; Pottage J C; Antoniskis D; McKinley G F; Hyslop N E; Ray G; Simon G; Reed N; LoFaro M L; Uttamchandani R B; Gelb L D; Sperber S J; Murphy R L; Leedom J M; Grieco M H; Zachary J; Hirsch M S; Spector S A; Bigley J; Soo W; Merigan T C
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
Annals of internal medicine 1993;118(5):321-30.
1993: Fischl M A
Treatment of HIV disease in 1993/1994.
AIDS clinical review 1993;():167-87.
1992: Henry D H; Beall G N; Benson C A; Carey J; Cone L A; Eron L J; Fiala M; Fischl M A; Gabin S J; Gottlieb M S
Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
Annals of internal medicine 1992;117(9):739-48.
1992: Fischl M A; Daikos G L; Uttamchandani R B; Poblete R B; Moreno J N; Reyes R R; Boota A M; Thompson L M; Cleary T J; Oldham S A
Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli.
Annals of internal medicine 1992;117(3):184-90.
1992: Fischl M A; Uttamchandani R B; Daikos G L; Poblete R B; Moreno J N; Reyes R R; Boota A M; Thompson L M; Cleary T J; Lai S
An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.
Annals of internal medicine 1992;117(3):177-83.
1992: Gelber R D; Lenderking W R; Cotton D J; Cole B F; Fischl M A; Goldhirsch A; Testa M A
Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group.
Annals of internal medicine 1992;116(12 Pt 1):961-6.
1992: Meng T C; Fischl M A; Boota A M; Spector S A; Bennett D; Bassiakos Y; Lai S H; Wright B; Richman D D
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Annals of internal medicine 1992;116(1):13-20.
1992: Bass H Z; Hardy W D; Mitsuyasu R T; Taylor J M; Wang Y X; Fischl M A; Spector S A; Richman D D; Fahey J L
The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.
Journal of acquired immune deficiency syndromes 1992;5(3):215-21.
1991: Lagakos S; Fischl M A; Stein D S; Lim L; Volberding P
Effects of zidovudine therapy in minority and other subpopulations with early HIV infection.
JAMA : the journal of the American Medical Association 1991;266(19):2709-12.
1991: Fischl M A
Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma.
The American journal of medicine 1991;90(4A):2S-7S.
1991: Fischl M A; Uttamchandani R B; Resnick L; Agarwal R; Fletcher M A; Patrone-Reese J; Dearmas L; Chidekel J; McCann M; Myers M
A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma.
Journal of acquired immune deficiency syndromes 1991;4(1):1-10.
1991: Fischl M A
New developments in dideoxynucleoside antiretroviral therapy for HIV infection.
AIDS clinical review 1991;():197-214.
1990: Gagnon S; Boota A M; Fischl M A; Baier H; Kirksey O W; La Voie L
Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial.
The New England journal of medicine 1990;323(21):1444-50.
1990: Fischl M A; Parker C B; Pettinelli C; Wulfsohn M; Hirsch M S; Collier A C; Antoniskis D; Ho M; Richman D D; Fuchs E
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
The New England journal of medicine 1990;323(15):1009-14.
1990: Fischl M; Galpin J E; Levine J D; Groopman J E; Henry D H; Kennedy P; Miles S; Robbins W; Starrett B; Zalusky R
Recombinant human erythropoietin for patients with AIDS treated with zidovudine.
The New England journal of medicine 1990;322(21):1488-93.
1990: Meng T C; Fischl M A; Richman D D
AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex.
The American journal of medicine 1990;88(5B):27S-30S.
1990: Fischl M A; Richman D D; Hansen N; Collier A C; Carey J T; Para M F; Hardy W D; Dolin R; Powderly W G; Allan J D
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Annals of internal medicine 1990;112(10):727-37.
1989: Fischl M A; Richman D D; Causey D M; Grieco M H; Bryson Y; Mildvan D; Laskin O L; Groopman J E; Volberding P A; Schooley R T
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.
JAMA : the journal of the American Medical Association 1989;262(17):2405-10.
1989: Merigan T C; Skowron G; Bozzette S A; Richman D; Uttamchandani R; Fischl M; Schooley R; Hirsch M; Soo W; Pettinelli C
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.
Annals of internal medicine 1989;110(3):189-94.
1989: Fischl M A
State of antiretroviral therapy with zidovudine.
AIDS (London, England) 1989;3 Suppl 1():S137-43.
1989: Fischl M A
Zidovudine: clinical experience in symptomatic HIV disease.
AIDS clinical review 1989;():221-42.
1988: Fournier A M; Dickinson G M; Erdfrocht I R; Cleary T; Fischl M A
Tuberculosis and nontuberculous mycobacteriosis in patients with AIDS.
Chest 1988;93(4):772-5.
1988: Fischl M A; Dickinson G M; La Voie L
Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.
JAMA : the journal of the American Medical Association 1988;259(8):1185-9.
1988: Yarchoan R; Perno C F; Thomas R V; Klecker R W; Allain J P; Wills R J; McAtee N; Fischl M A; Dubinsky R; McNeely M C
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
Lancet 1988;1(8577):76-81.
1988: Parks W P; Parks E S; Fischl M A; Leuther M D; Allain J P; Nusinoff-Lehrman S; Barry D W; Makuch R W
HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trail.
Journal of acquired immune deficiency syndromes 1988;1(2):125-30.
1988: Fischl M A
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
AIDS (London, England) 1988;2 Suppl 1():S143-50.
1988: Yarchoan R; Thomas R V; Grafman J; Wichman A; Dalakas M; McAtee N; Berg G; Fischl M; Perno C F; Klecker R W
Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease.
Annals of neurology 1988;23 Suppl():S82-7.
1987: Richman D D; Fischl M A; Grieco M H; Gottlieb M S; Volberding P A; Laskin O L; Leedom J M; Groopman J E; Mildvan D; Hirsch M S
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
The New England journal of medicine 1987;317(4):192-7.
1987: Fischl M A; Richman D D; Grieco M H; Gottlieb M S; Volberding P A; Laskin O L; Leedom J M; Groopman J E; Mildvan D; Schooley R T
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
The New England journal of medicine 1987;317(4):185-91.
1987: Berger J R; Moskowitz L; Fischl M; Kelley R E
Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome.
Southern medical journal 1987;80(6):683-6.
1987: Fischl M A; Dickinson G M; Scott G B; Klimas N; Fletcher M A; Parks W
Evaluation of heterosexual partners, children, and household contacts of adults with AIDS.
JAMA : the journal of the American Medical Association 1987;257(5):640-4.
1987: Yarchoan R; Berg G; Brouwers P; Fischl M A; Spitzer A R; Wichman A; Grafman J; Thomas R V; Safai B; Brunetti A
Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.
Lancet 1987;1(8525):132-5.
1987: Fletcher M A; Baron G C; Ashman M R; Fischl M A; Klimas N G
Use of whole blood methods in assessment of immune parameters in immunodeficiency states.
Diagnostic and clinical immunology 1987;5(2):69-81.
1986: Schein R M; Fischl M A; Pitchenik A E; Sprung C L
ICU survival of patients with the acquired immunodeficiency syndrome.
Critical care medicine 1986;14(12):1026-7.
1986: Fischl M A; Dickinson G M
Fansidar prophylaxis of Pneumocystis pneumonia in the acquired immunodeficiency syndrome.
Annals of internal medicine 1986;105(4):629.
1986: Post M J; Hensley G T; Moskowitz L B; Fischl M
Cytomegalic inclusion virus encephalitis in patients with AIDS: CT, clinical, and pathologic correlation.
AJR. American journal of roentgenology 1986;146(6):1229-34.
1986: Fischl M A
Patient tolerance to interferon: clinical and laboratory assessments.
The Medical clinics of North America 1986;Suppl():41-5.
1986: Fischl M A; Dickinson G M; Sinave C; Pitchenik A E; Cleary T J
Salmonella bacteremia as manifestation of acquired immunodeficiency syndrome.
Archives of internal medicine 1986;146(1):113-5.
1985: Greenberg J E; Fischl M A; Berger J R
Upper airway obstruction secondary to acquired immunodeficiency syndrome-related Kaposi's sarcoma.
Chest 1985;88(4):638-40.
1985: Fischl M A; Pitchenik A E; Spira T J
Tuberculous brain abscess and Toxoplasma encephalitis in a patient with the acquired immunodeficiency syndrome.
JAMA : the journal of the American Medical Association 1985;253(23):3428-30.
1985: Pitchenik A E; Spira T J; Elie R; Fischl M A; Getchell J P; Arnoux E; Pierre G D; Laroche A C; Guerin J M; Malebranche R
Prevalence of HTLV-III/LAV antibodies among Haitians.
The New England journal of medicine 1985;312(26):1705-6.
1985: Scott G B; Fischl M A; Klimas N; Fletcher M A; Dickinson G M; Levine R S; Parks W P
Mothers of infants with the acquired immunodeficiency syndrome. Evidence for both symptomatic and asymptomatic carriers.
JAMA : the journal of the American Medical Association 1985;253(3):363-6.
1985: Pitchenik A E; Fischl M A; Saldana M J
Kaposi's sarcoma of the tracheobronchial tree. Clinical, bronchoscopic, and pathologic features.
Chest 1985;87(1):122-4.
1985: Baron G C; Klimas N G; Fischl M A; Fletcher M A
Decreased natural cell-mediated cytotoxicity per effector cell in acquired immunodeficiency syndrome.
Diagnostic immunology 1985;3(4):197-204.
1984: Whiteside M E; Barkin J S; May R G; Weiss S D; Fischl M A; MacLeod C L
Enteric coccidiosis among patients with the acquired immunodeficiency syndrome.
The American journal of tropical medicine and hygiene 1984;33(6):1065-72.
1984: Pitchenik A E; Cole C; Russell B W; Fischl M A; Spira T J; Snider D E
Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida.
Annals of internal medicine 1984;101(5):641-5.
1984: Pardo V; Aldana M; Colton R M; Fischl M A; Jaffe D; Moskowitz L; Hensley G T; Bourgoignie J J
Glomerular lesions in the acquired immunodeficiency syndrome.
Annals of internal medicine 1984;101(4):429-34.
1984: Fischl M A; Dickinson G M
An acquired immunodeficiency syndrome among Haitians: an update.
Annals of the New York Academy of Sciences 1984;437():325-33.
1983: Pitchenik A E; Fischl M A; Spira T J
Acquired immune deficiency syndrome in low-risk patients. Evidence for possible transmission by an asymptomatic carrier.
JAMA : the journal of the American Medical Association 1983;250(10):1310-2.
1983: Pitchenik A E; Fischl M A; Walls K W
Evaluation of cerebral mass lesions in acquired immunodeficiency syndrome.
The New England journal of medicine 1983;308(18):1099.
1983: Pitchenick A E; Fischl M A
Prevention of acquired immunodeficiency syndrome.
Annals of internal medicine 1983;98(4):558-9.
1983: Pitchenik A E; Fischl M A; Dickinson G M; Becker D M; Fournier A M; O'Connell M T; Colton R M; Spira T J
Opportunistic infections and Kaposi's sarcoma among Haitians: evidence of a new acquired immunodeficiency state.
Annals of internal medicine 1983;98(3):277-84.
1983: Pitchenik A E; Fischl M A
Disseminated tuberculosis and the acquired immunodeficiency syndrome.
Annals of internal medicine 1983;98(1):112.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Margaret Fischl

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Margaret Fischl (preview)

All Publications